{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-096765","form_type":"8-K","ticker":"IMA","cik":"0001835579","company_name":"ImageneBio, Inc.","filed_at":"2022-04-06T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.713710+00:00","generated_at":"2026-06-26T09:11:46.931035+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Ikena Oncology advances IK-175 combination cohort to stage two in Phase 1b trial for urothelial carcinoma","bullets":["IK-175 (AHR antagonist) Phase 1b trial (NCT04200963) combination with nivolumab expansion cohort advanced to stage two in April 2022.","Patients are advanced/metastatic urothelial carcinoma progressed after multiple prior therapies including checkpoint inhibitors.","Simon two-stage design requires predefined ORR threshold (RECIST 1.1) to be met in stage one before advancing to stage two.","Monotherapy expansion cohort had previously advanced to stage two in September 2021.","Initial clinical data from the trial expected to be submitted to an oncology conference in H2 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-096765","json":"https://secwatch.observer/filing/0001193125-22-096765.json","markdown":"https://secwatch.observer/filing/0001193125-22-096765.md","text":"https://secwatch.observer/filing/0001193125-22-096765.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835579/000119312522096765/0001193125-22-096765-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835579/000119312522096765/d311568d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T09:11:46.931035+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}